HOUSTON, July 17, 2019 /PRNewswire/ -- Marker
Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced it will host a conference call and webcast with a
question-and-answer session on Monday, July
22, 2019 at 5:30 a.m. PDT/
8:30 a.m. EDT to review data from an
investigator-sponsored Phase 1/2 clinical trial with its MultiTAA
therapy in patients with pancreatic adenocarcinoma. The data will
also be reviewed in plenary and poster sessions on Saturday, July 20 at a cell therapy conference
hosted by the American Association for Cancer Research (AACR) in
San Francisco by Brandon G. Smaglo, M.D., FACP, Assistant
Professor, Medical Director of Hematology/Oncology at the Baylor
College of Medicine, Houston,
Texas.
The live conference call and webcast will be accessible in
the Investors section of the Company's website
at www.markertherapeutics.com. The archived webcast will be
available for replay on the Marker website following the event.
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in
the development of next-generation T cell-based immunotherapies for
the treatment of hematological malignancies and solid tumor
indications. Marker's cell therapy technology is based on the
selective expansion of non-engineered, tumor-specific T cells that
recognize tumor associated antigens (i.e. tumor targets) and kill
tumor cells expressing those targets. This population of T cells is
designed to attack multiple tumor targets following infusion into
patients and to activate the patient's immune system to produce
broad spectrum anti-tumor activity. Because Marker does not
genetically engineer its T cells therapies, we believe that our
product candidates will be easier and less expensive to
manufacture, with reduced toxicities, compared to current
engineered CAR-T and TCR-based approaches, and may provide patients
with meaningful clinical benefit. As a result, Marker believes its
portfolio of T cell therapies has a compelling product profile, as
compared to current gene-modified CAR-T and TCR-based
therapies.
Marker is also advancing a number of innovative peptide- and
gene-based immuno-therapeutics for the treatment of metastatic
solid tumors, including the Folate Receptor Alpha program (TPIV200)
for breast and ovarian cancers and the HER2/neu program
(TPIV100/110) for breast cancer, currently in Phase 2 clinical
trials.
To receive future press releases via email, please
visit: https://markertherapeutics.com/email-alerts/
Forward-Looking Statement Disclaimer
This release
contains forward-looking statements for purposes of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Statements in this news release concerning the Company's
expectations, plans, business outlook or future performance, and
any other statements concerning assumptions made or expectations as
to any future events, conditions, performance or other matters, are
"forward-looking statements." Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
our research and development activities relating to our
non-engineered multi-tumor antigen specific T cell therapies; our
TPIV200 and TPIV100/110 programs; the effectiveness of these
programs or the possible range of application and potential
curative effects and safety in the treatment of diseases; and, the
timing and success of our clinical trials, as well as clinical
trials conducted by our collaborators. Forward-looking statements
are by their nature subject to risks, uncertainties and other
factors which could cause actual results to differ materially from
those stated in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the
Company's most recent Form 10-K, 10-Q and other SEC filings which
are available through EDGAR at www.sec.gov. The Company assumes no
obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-host-conference-call-and-webcast-to-review-interim-results-from-phase-12-clinical-trial-with-its-multitaa-t-cell-therapy-in-patients-with-pancreatic-adenocarcinoma-300886184.html
SOURCE Marker Therapeutics, Inc.